arrow
J

Joshua Fein

weill cornell medical college
H指数:23
被引数:2,353

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world assessment of prophylactic anakinra on neurotoxicity and cytokine release syndrome after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysis

R/R B细胞淋巴瘤患者接受CD19 CAR T细胞疗法后,预防性使用阿那白滞素对神经毒性和细胞因子释放综合征影响的真实世界评估:一项逆概率治疗加权分析

2026-06-170
PRE
Outcomes of terminal complement blockade in adults with high-risk transplant-associated thrombotic microangiopathy: a comparative analysis

高危移植相关血栓性微血管病成人中终末补体阻滞的结局:一项比较分析

2025-11-280
PRE
Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse posttransplant

骨髓和血液显示出不同的免疫重建模式,并与移植后的复发存在关联。

2025-06-140
OAAI
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort

在接受CD19 CAR T细胞治疗的淋巴瘤患者中,从广泛的抗真菌预防转变为量身定制的抗真菌预防: 来自大型回顾性队列的结果

2025-01-010
OAAI
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy

CD19嵌合抗原受体T细胞治疗后肾损伤的预测及意义

2024-11-211
OAAI
CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma
2024-10-100
OAAI
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
2024-07-241
OAAI
Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight
2024-04-027
OAAI
Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma

大b细胞淋巴瘤中嵌合抗原受体T细胞治疗后的异基因造血细胞移植

2023-02-0116
PRE
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
LEUKEMIA
IF13.4
2022-11-0536
OA
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma

维生素d不足与嵌合抗原受体T细胞治疗大b细胞淋巴瘤的临床结局

2022-11-014
OAAI
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT
2022-03-0321
OAAI